Kubota, Eiji <br/><br/>
ERas enhances resistance to CPT-11 in gastric cancer.  [electronic resource] 

 -  Anticancer research  Oct 2011 
 - 3353-60 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1791-7530 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Camptothecin--analogs & derivatives<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>DNA--metabolism<br/>DNA Topoisomerases, Type I--metabolism<br/>Drug Resistance, Neoplasm--drug effects<br/>Embryonic Stem Cells--drug effects<br/>Gene Expression Profiling<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Humans<br/>Inhibitory Concentration 50<br/>Irinotecan<br/>Models, Biological<br/>NF-kappa B--metabolism<br/>Protein Binding--drug effects<br/>Sirolimus--pharmacology<br/>Stomach Neoplasms--drug therapy<br/>Up-Regulation--drug effects<br/>ras Proteins--metabolism